The FDA has suspended the licensing of a chikungunya vaccine, Ixchiq, due to safety concerns, which may shift focus to an alternative, Vimkunya. Meanwhile, the US government has expanded its smallpox stockpile through a contract, although it is unclear if this is related to the Ixchiq suspension. The expansion includes international orders, but the connection to the chikungunya vaccine suspension is not specified.